Your browser doesn't support javascript.
loading
Vasopressors and Nutrition Therapy: Safe Dose for the Outset of Enteral Nutrition?
Simo Es Covello, Luís Henrique; Gava-Brandolis, Marcella Giovana; Castro, Melina Gouveia; Dos Santos Netos, Martins Fidelis; Manzanares, William; Toledo, Diogo Oliveira.
Afiliação
  • Simo Es Covello LH; Department of Critical Care of Barretos Cancer Hospital, Barretos, Brazil.
  • Gava-Brandolis MG; Department of Research of Hospital Sa˜o Luis Itaim, Sa˜o Paulo, Brazil.
  • Castro MG; Department of Education of Hospital Israelita Albert Einstein, Sa˜o Paulo, Brazil.
  • Dos Santos Netos MF; Department of Science Information of Barretos Cancer Hospital, Barretos, Brazil.
  • Manzanares W; Department of Critical Care, University Hospital of Universidad de la Republica (UDELAR), Montevideo, Uruguay.
  • Toledo DO; Department of Critical Care of Hospital Israelita Albert Einstein, Sa˜o Paulo, Brazil.
Crit Care Res Pract ; 2020: 1095693, 2020.
Article em En | MEDLINE | ID: mdl-32104602
ABSTRACT
BACKGROUND AND

AIMS:

Patients with hemodynamic instability need to receive intensive treatment as fluid replacement and vasoactive drugs. In the meantime, it is supposed to initiate nutritional therapy within 24 to 48 hours after admission to the intensive care unit (ICU), as an essential part of patient's intensive care and better outcomes. However, there are many controversies tangential to the prescription of enteral nutrition (EN) concomitant to the use of vasopressor and its doses. In this way, the present study aimed to identify what the literature presents of evidence to guide the clinical practice concerning the safe dose of vasopressors for the initiation of nutritional therapy in critically ill patients.

METHODS:

This review was carried out in PubMed, ProQuest, Web of Science, and Medline databases. The descriptors were used to perform the search strategy Critical Care, Intensive Care Units, Vasoconstrictor Agents, and Enteral Nutrition. Inclusion criteria were patients of both genders, over 18 years of age, using vasoactive drugs, with the possibility of receiving EN therapy, and articles written in English, Portuguese, and Spanish. In addition, exclusion criteria were case reports, non-papers, and repeated papers.

RESULTS:

10 articles met our inclusion criteria.

CONCLUSION:

It was observed that there are many controversies about the supply of EN in critically ill patients using vasopressor, especially about the safe dose, and it was not possible to identify a cutoff value for the beginning therapy. Despite the drug doses, clinical signs are still the most important parameters in the evaluation of EN tolerance.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article